Please assess the completion status of the following clinical trial:

Trial Title: MPS II Immunophenotyping

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subject has a confirmed diagnosis of Mucopolysaccharidosis type II (MPS II) or Hunter Syndrome based on enzyme activity and variant analysis.~* Subject who plan to receive or have received enzyme replacement therapy with idursulfase.~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Naive (Type: None): Subjects who are naïve to ERT and start treatment with idursulfase
- Treatment less than 3 years (Type: None): Subjects who have received ERT for \<3 years
- Treatment over 3 years (Type: None): Subjects who have received ERT for 3 or more years

Based on this trial design, predict the completion outcome and termination type (if applicable).